Brochures: Extractables & leachables services
Posted: 19 February 2020 | SGS Life Sciences | No comments yet
Why do E&L testing? Extractables & leachables studies enable drug sponsors to quantify and identify the risks of potentially toxic leachable impurities migrating into a drug solution from container closure systems, processing equipment or packaging.
Regulatory bodies such as the US Food and Drug Administration (FDA) and The European Medicines Agency (EMA) are increasingly focusing on the interactions between various manufacturing components (such as single use systems), drug delivery devices and container-closure systems, and the finished pharmaceutical product.
The FDA has stated in its packaging guideline from 1999 that “Drug product containers and closures shall not be reactive, additive, or absorptive so as to alter the safety, identity, strength, quality or purity of the drug beyond the official or established requirements.” Consequently, extractables and leachables (E&L) studies are crucial component of product release.
Related content from this organisation
- Press Release: Overcoming contamination risks during biologicals production: Mycoplasma & virus testing
- Webinar: Overcoming contamination risks during biologicals production: Mycoplasma & virus testing
- SGS joins forces with Agilex Biolabs
- SGS ISL marks two-year anniversary
- Whitepaper: Changing regulatory environment for nitrosamine impurities
Related topics
Drug Delivery Systems, Manufacturing, Regulation & Legislation, Single Use